Executive Director, Oncology Portfolio Leader, Clinical Pharmacology and Pharmacometrics
Daiichi Sankyo, Inc.
Yvonne Lau, PhD, is currently an Executive Director and Oncology Portfolio Lead within Quantitative Clinical Pharmacology Department at Daiichi Sankyo, Inc. Her group provides strategic clinical pharmacology and pharmacometrics support to early to late oncology programs across different molecule modalities (small molecule, mAb, ADC). Prior to joining Daiichi Sankyo, Yvonne held roles in the Oncology Clinical Pharmacology department at Janssen and Novartis with increasing responsibilities. Before joining Novartis, she worked at the Clinical Pharmacology group at Amgen and Medimmune. Yvonne earned her Ph.D. in Biopharmaceutical Sciences from University of California at San Francisco. She has more than 15 years of industry experience in the clinical development of small molecules and biologics across various therapeutic areas. She also worked on a number of successful NDA/MAA filings with extensive experiences in global regulatory interactions.